Credit rating agency ICRA has assigned Bliss GVS Pharma an 'ICRA A (Stable)' long-term and 'ICRA A2' short-term rating for their ₹100 crore facilities, indicating a strong credit profile. The evaluation covers both fund-based and non-fund-based facilities, with a scheduled review within the year.

Analysts recommend investing in Kakatiya Cement, Bliss GVS Pharma, and Arvind as market volatility offers potential buy opportunities. Suggested price targets are Rs 105-120 for Kakatiyas, Rs 245 for Bliss GVS, and Rs 430 for Arvind. For risk management, it's advised to set stop-losses.